百令胶囊联合紫杉醇+顺铂化疗在非小细胞肺癌合并肺结核患者中的应用效果  

Application effect of Bailing capsule combined with paclitaxel+cisplatin chemotherapy in patients with non-small cell lung cancer complicated with pulmonary tuberculosis

作　　者：孙冰[1] 杨亚勤[2] 黄健[3] 崔秀琴[4] SUN Bing;YANG Yaqin;HUANG Jian;CUI Xiuqin(First Ward,Department of Tuberculosis,the First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,He’nan,China;Department of Emergency,the First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,He’nan,China;Department of Respiratory Endoscopy,the First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,He’nan,China;Second Ward,Department of Tuberculosis,the First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,He’nan,China)

机构地区：[1]新乡医学院第一附属医院结核科一病区,河南新乡453100 [2]新乡医学院第一附属医院急诊科,河南新乡453100 [3]新乡医学院第一附属医院呼吸内镜科,河南新乡453100 [4]新乡医学院第一附属医院结核科二病区,河南新乡453100

出　　处：《癌症进展》2025年第8期936-939,共4页Oncology Progress

摘　　要：目的目的探讨百令胶囊联合紫杉醇^(+)顺铂化疗在非小细胞肺癌(NSCLC)合并肺结核患者中的应用效果。方法方法依据治疗方式的不同将150例NSCLC合并肺结核患者分为对照组(n=72)和观察组(n=78),两组患者均接受标准方案肺结核治疗,在此基础上,对照组患者接受紫杉醇^(+)顺铂治疗,观察组患者接受百令胶囊联合紫杉醇^(+)顺铂治疗。比较两组患者的临床疗效、免疫功能指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、凝血功能指标[D-二聚体(D-D)、纤维蛋白原(FIB)]、不良反应发生情况及生活质量[欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)]。结果结果观察组患者的治疗总有效率为58.97%,高于对照组患者的40.28%,差异有统计学意义(P﹤0.05)。治疗后,两组患者CD4^(+)水平及CD4^(+)/CD8^(+)均高于本组治疗前,CD8^(+)水平均低于本组治疗前,观察组患者CD4^(+)水平及CD4^(+)/CD8^(+)均高于对照组,CD8^(+)水平低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者D-D、FIB水平均低于本组治疗前,观察组患者D-D、FIB水平均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者EORTC QLQ-C30各维度评分均高于本组治疗前,观察组患者EORTC QLQ-C30各维度评分均高于对照组,差异均有统计学意义(P﹤0.05)。观察组患者的不良反应总发生率为39.74%,低于对照组患者的56.94%,差异有统计学意义(P﹤0.05)。结论结论百令胶囊联合紫杉醇^(+)顺铂化疗可有效提高NSCLC合并肺结核患者的免疫功能,改善凝血功能指标,降低不良反应发生率,提高患者的生活质量。Objective To explore the application effect of Bailing capsule combined with paclitaxel^(+)cisplatin che-motherapy in patients with non-small cell lung cancer(NSCLC)complicated with pulmonary tuberculosis.Method Ac-cording to different treatment methods,150 patients with NSCLC complicated with pulmonary tuberculosis were divided into control group(n=72)and observation group(n=78).Both groups received standard pulmonary tuberculosis treat-ment,on this basis,the control group received paclitaxel^(+)cisplatin treatment,while the observation group received Bail-ing capsule combined with paclitaxel^(+)cisplatin treatment.The clinical efficacy,immune function indicators(CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),coagulation function indicators[D-dimer(D-D),fibrinogen(FIB)],incidence of adverse events,and quality of life[European Organization for Research and Treatment of Cancer quality of life questionnaire core 30(EORTC QLQ-C30)]were compared between the two groups.Result The total effective rate in observation group was 58.97%,which was higher than 40.28%in control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CD4^(+),CD4^(+)/CD8^(+)in both groups were higher than those before treatment,while the CD8^(+)levels were lower than those before treatment,the levels of CD4^(+),CD4^(+)/CD8^(+)in observation group were higher than those in control group,while the CD8^(+)level was lower than that in control group,and the differences were statistically significant(P<0.05).After treatment,the levels of D-D and FIB in both groups were lower than those before treatment,the levels of D-D and FIB in observation group were lower than those in control group,and the differences were statistically signifi-cant(P<0.05).After treatment,the scores of dimensions of EORTC QLQ-C30 in both groups were higher than those be-fore treatment,the scores of dimensions of EORTC QLQ-C30 in observation group were higher than those in control group,and the differences were statistically significant(P<0.05).The total i

关 键 词：百令胶囊 非小细胞肺癌 肺结核 免疫功能 凝血功能 不良反应 生活质量 

分 类 号：R734.2[医药卫生—肿瘤]